Aiming for protective T-cell responses: A focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials

Registros relacionados

• Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
  por: Ondondo, B, et al.
  Publicado em: (2013)
• Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice
  por: Ondondo, B, et al.
  Publicado em: (2013)
• Optimizing Delivery of the HIVconsv Immunogen in Rhesus Macaques
  por: Rosario, M, et al.
  Publicado em: (2011)
• Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques
  por: Borthwick, N, et al.
  Publicado em: (2015)
• Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
  por: Hancock, G, et al.
  Publicado em: (2017)